1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
HEAL Initiative: Translating Addiction Epidemiology, Prevention, Treatment, and Recovery Research into Practice (R61/R33 - Clinical Trial Optional) is sponsored by National Institute on Drug Abuse (NIDA) / NIH HEAL Initiative. This funding opportunity supports action-oriented research to accelerate the translation of addiction epidemiology, prevention, treatment services, and recovery research into practice to address the opioid crisis and/or overdose events.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Opportunity Listing - HEAL: Translating Addiction Epidemiology, Prevention, Treatment, and Recovery Research into Practice (R61/R33 - Clinical Trial Optional) HEAL: Translating Addiction Epidemiology, Prevention, Treatment, and Recovery Research into Practice (R61/R33 - Clinical Trial Optional) Agency: National Institutes of Health Assistance Listings: 93.
279 -- Drug Use and Addiction Research Programs Last Updated: June 5, 2026 View version history on Grants.
gov The National Institute on Drug Abuse (NIDA), with other NIH Institutes, intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications to support action-oriented research that accelerates the translation of addiction epidemiology, prevention, treatment, and recovery research to practice addressing both the opioid crisis and overdose events.
Research supported under this initiative would focus on identifying and characterizing malleable factors and addressing barriers or facilitators to reducing substance use, misuse and overdose deaths at the individual, provider, organizational, community, or system levels.
The emphasis would be on exploring and developing effective, replicable, and scalable approaches for accelerating the movement of evidence-based and promising treatments and preventive interventions into routine use.
Specific priority areas would include, but not be limited to: recovery, prevention, pain/addiction intersections, engaging family and loved ones, transitions across care settings (e.g., inpatient treatment to community treatment), mental health integration, improving quality and efficiency of existing services and interventions, examining substance use and health outcomes and meaningful real-time data capture and use to improve services and public health approaches to reducing substance use, misuse, addiction, and overdose.
Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This NOFO will utilize the R61/R33 activity code.
Investigators with expertise and insights into this area of addiction epidemiology, prevention, treatment, recovery and health services research are encouraged to begin to consider applying for this new NOFO.
In addition, collaborative investigations combining expertise in modeling, health economics, implementation science, translation, or engagement science will be encouraged, and these investigators should also begin considering applying for this application.
Federally recognized Native American tribal governments Public and Indian housing authorities Public and state institutions of higher education Independent school districts Private institutions of higher education Other Native American tribal organizations Nonprofits non-higher education with 501(c)(3) For-profit organizations other than small businesses Grantor contact information No documents are currently available.
Link to additional information Funding opportunity number : Cost sharing or matching requirement : Funding instrument type : Opportunity Category Explanation : Category of Funding Activity : Your account requires additional identity verification.
According to the current listing, eligibility includes: Eligible applicants include independent school districts, public and state institutions of higher education, private institutions of higher education, various government entities (county, city, federally recognized Nati…. Confirm the full requirements in the official notice before applying.
Applications for HEAL Initiative: Translating Addiction Epidemiology, Prevention, Treatment, and Recovery Research into Practice (R61/R33 - Clinical Trial Optional) are due February 9, 2029. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
HEAL Initiative: Translating Addiction Epidemiology, Prevention, Treatment, and Recovery Research into Practice (R61/R33 - Clinical Trial Optional) is funded by National Institute on Drug Abuse (NIDA) / NIH HEAL Initiative. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional) is sponsored by National Institute on Drug Abuse (NIDA) / NIH HEAL Initiative. Part of the NIH HEAL Initiative, this funding opportunity supports the development of interventions to prevent and treat substance use disorders and overdose. It focuses on therapeutics development and may involve clinical trials.
HEAL Initiative: Research Studies to Develop and Implement Interventions to Prevent Opioid Misuse in Community Health Centers (RFA-DA-23-048) is sponsored by National Institute on Drug Abuse (NIDA) / NIH HEAL Initiative. This funding opportunity supports interdisciplinary teams to study the development, adaptation, and/or implementation of interventions to prevent misuse of opioids and other substances in community health centers.
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articlePA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read article